testing, it is go back to old board
I'm a little concerned abourt proposal 5. (plan of reorganization) Long time holder of the Micro-cap fund.
Wasatch reps have called me twice asking if I have voted.
Is there something here I'm missing or is my concerns unjustified?
Thanks to anyone who can provide more info
NEEDHAM, Mass. & BRANFORD, Conn.--(BUSINESS WIRE)--May. 29, 2009-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced it has entered into a definitive agreement to acquire CuraGen Corporation (Nasdaq: CRGN). The acquisition will add a portfolio of oncology-focused, fully-owned antibodies to Celldex’s Precision Targeted Immunotherapy Platform. Celldex will acquire CuraGen in a tax-free stock-for-stock transaction, which values CuraGen...
Celldex Presents Results from Phase 1 Studies of CDX-1307 with GM-CSF
--CDX-1307 well tolerated with good immune responses observed
excerpt from the article:
Next, she explained that she and her research partner had developed a vaccine that, in GBM grade 4 patients with that mutant gene, almost doubles life expectancy compared with that of GBM patients who receive only chemotherapy.
I was ready to roll up my sleeves and get to it then and there, but she said we'd have to wait until my first MRI, which they'd do about a month after my chemo and radiation. If it was clean - no tumors - I could enroll in the program.
Okay. Good. I understand. Put me on the waiting list.
But what about this Double Whammy business?
The Double Whammy clinical trial got liftoff (and its name) because Dr. Sam Hassenbusch, a prominent brain surgeon thereat MDA, had a GBM of his own removed in May 2005. When it came time for his treatment, Dr. Heimberger said, the question came down to a vaccine (which is a form of immunotherapy) or chemo, the two traditional forms of treating GBMs. Why not both? Dr. Sam asked.
(That's what everybody at MDA called him. That's what we started calling him when we met him a little later that day. Tori had read about Dr. Sam in Newsweek back in December, and had urged us to try to meet him when we went back in January after surgery.)
Nobody's ever done both, Dr. Heimberger told him. The combination could kill you.
Dr. Sam's response, as reported in a March 2007 CBS interview with Katie Couric, was typical of the kind of guy we found him to be: "Don't worry about it. Look, just think of me as a six-foot-tall research rat. And go ahead and do whatever you would do to a rat."
Then he explained in a more serious vein why he was willing to serve as a research rat: "Try it on me. If it works, that's great. If it doesn't, well, that's why I've devoted my life to medicine."
And that's how Dr. Sam became enrollee number one in what he and Dr. Heimberger dubbed the Double Whammy trial.
That was back in August 2005. When Kay and I met him in January 2007, he was serving as a consultant at MDA. The man exuded unbelievable enthusiasm for life. We agreed after our first meeting with him that he was one of the most charismatic persons that we had ever met.
So after getting a clear MRI a month after completing my seven-week chemo-radiation treatment cycle, I became enrollee number six in the Double Whammy. As you know, I've always been partial to number one, but I respectfully tip my Yankee cap to the man who earned that distinction in the Double Whammy: Dr. Sam Hassenbusch.
There are about 20 people enrolled in the Double Whammy trial that I'm participating in. Kay and I have been in touch with most of them. And here's a bulletin from the It's a Small World Bureau - Bob Sheppard's daughter, Barbara Derenowski, who lives in Arizona, is also in the Double Whammy trial. She enrolled five months before I did.
Nice article in today's NY Post on Bobby Murcers battle with brain cancer. Part of the article dicusses his vaccine treatment. No mention of avan,cdx-110 or celledx by name.
AVANT to Host Conference Call Today, April 16, 2008, at 5:00 PM to Discuss CDX-110 Partnership with Pfizer
4:41 p.m. 04/16/2008
NEEDHAM, Mass., Apr 16, 2008 (BUSINESS WIRE) -- AVANT Immunotherapeutics, Inc. (AVAN) will hold a conference call today at 5:00 PM ET to discuss today's announcement of an exclusive worldwide licensing and development agreement between AVANT, acting through its wholly-owned subsidiary Celldex Therapeutics, Inc., and Pfizer for CDX-110. CDX-110, a therapeutic cancer vaccine candidate, is in Phase 2 development for the treatment of glioblastoma multiforme (GBM).
To access the live call, dial 866-383-8009 (within the United States) or 617-597-5342 (outside the United States). The passcode for participants is 83919284. The call will also be available live on the Company's website www.avantimmune.com in the Investor Information, Investor Overview section.
A replay will be available approximately two hours after the live call until April 23, 2008. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The replay passcode is 71323547. The replay will also be available on the Company's website www.avantimmune.com .
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics and Celldex Therapeutics combined during the first quarter of 2008. AVANT is a NASDAQ-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is exploiting its access to proprietary human antibody technology for development of therapeutic monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development. Identification of the potential of EGFRvIII in cancer diagnosis, prevention and therapy was based on the collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Application of this discovery toward the development of the CDX-110 vaccine was further advanced by Dr. John Sampson and his colleagues at the Duke University Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD Anderson Cancer Center. AVANT also has several product candidates in its development pipeline including:
-- CDX-1307, a product based on its proprietary APC Targeting Technology(TM), which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast and colon cancer;
-- TP10, a complement inhibitor, in development for transplantation and other indications; and
-- Three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military and global health needs.
AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs. For more information on AVANT or Pfizer or please visit www.avantimmune.com or www.pfizer.com .